-
CDC: Recent Decline Seen in High-Grade Cervical Lesions
drugs
April 19, 2019
CDC: Recent Decline Seen in High-Grade Cervical Lesions
-
Some Patients With Imminently Fatal Cancer Undergo Treatment
drugs
April 18, 2019
Some patients with imminently fatal de novo metastatic cancer undergo treatment.
-
New micro-platform improves understanding of cancer cells
europeanpharmaceuticalreview
April 18, 2019
A new low-cost, cell culture platform technique may provide insight for more effective cancer treatment, according to the researchers who developed it…
-
Roche's drugs, new and old, team up for major sales—sans price hikes
fiercepharma
April 18, 2019
Last July, Roche put a halt on drug price increases in the U.S. But that didn't stop five of its products from topping analysts' sales estimates by double digits to start the year.
-
Durvalumab improves survival of non-small cell lung cancer patients
europeanpharmaceuticalreview
April 18, 2019
Moffitt researchers conducted a Phase III trial which found durvalumab to increase the survival of patients with non-small cell lung cancer…
-
Cellesce Announces License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Breast Cancer Organoids at Scale
b3cnewswire
April 17, 2019
Cellesce Announces License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Breast Cancer Organoids at Scale.
-
FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
drugs
April 17, 2019
FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer.
-
FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer
drugs
April 17, 2019
FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer.
-
Rexahn & BioSense Enter License Agreement
contractpharma
April 17, 2019
To advance the development and commercialization of RX-3117 for pancreatic cancer and other cancers in Greater China...
-
Qiagen launches first FGFR-based cancer diagnostic
fiercebiotech
April 17, 2019
Alongside Janssen’s accelerated approval of Balversa as the first targeted therapy for metastatic bladder cancer, the FDA also greenlighted Qiagen’s companion diagnostic test to ...